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2013. Seven other countries were excluded as either there was incomplete information 
(n  4) or information was partially in their native language (n  3). Parameters evalu-
ated were: number of diseases monitored, case deﬁ nition, presentation of data, and
periodicity of data presentation. Websites were accessed from December 4 – December
7, 2008. RESULTS: Information on the number of diseases monitored varied across
countries, namely, 64 (U.S.), 66 (Canada), 66 (Australia), and 51 (New Zealand), 
respectively. There was lack of consistency in case deﬁ nitions, data presentation, and 
the type of data accessed on their websites. The US presented raw data in the form 
of ‘Morbidity and Mortality Weekly Report’ and elaborated annual reports, available
unto 2006. Canada reported raw data monthly and annual reports available until
2004. Australia reported raw data fortnightly and annual reports available into 2006.
No such detailed information was available on the surveillance website for New
Zealand. CONCLUSIONS: There exists discrepancy in the disease surveillance web-
sites for the countries, in reporting surveillance data and related information. Infec-
tious diseases can achieve epidemiological proportions, hence, there needs to be more
concerted efforts in harmonizing structure of the surveillance networks and data pre-
sentation. Harmonization efforts taken by the ‘European Centre for Disease Preven-
tion and Control’ once published, may be considered by other countries.
PHP58
FACTORS ASSOCIATED WITH REPEAT ATTENDANCE AT EMERGENCY
DEPARTMENT (ED) OF A SECONDARY CARE HOSPITAL IN SINGAPORE
Paul P1, Heng BH1, Tay SY2, Seow E3
1National Healthcare Group, Singapore, Singapore, 2Tan Tock Seng Hospital, Singapore, 
Singapore, 3Tan Tock Seng Hospital, Singapore, Singapore, Singapore
OBJECTIVES: To determine factors associated with repeat attendance at emergency 
department (ED) of a secondary care hospital in Singapore. METHODS: An analysis
of data from the EDWeb of all patients who attended ED between January 1, 2005 
and December 31, 2007 was performed. Variables considered in the analysis were age,
gender, race, date of attendance, and diagnosis based on ICD-9CM code. Frequency 
of ED attendance was categorized into index attendance, repeat attendance and high 
impact attendance. Index attendance refers to the ﬁ rst visit by the patient to the ED.
Repeat attendance refers to more than one visit by the same patient. High impact
attendance refers to patients with 5 ED visits. RESULTS: There was a total of 
141,642, 142,820, 160,096 ED attendances in 2005, 2006, and 2007, respectively. 
Of these, 22–24% were by elderly patients (65 years), and 27%–28% were repeat 
attendance. Repeat attendance rate increased with age, with highest rates among those
aged 75 years (36%–38%) and signiﬁ cantly higher among young males, older
females, and those presenting with chronic obstructive pulmonary disease, respiratory 
infections, pneumonia, diabetes and heart failure. High impact attendance comprised
7–11% of total attendance and have increased by 12% among persons aged 75 over 
the period 2005–2007. Majority (60%) were males. CONCLUSIONS: Repeat atten-
dance constitute more than one fourth of total ED attendance and is marked among
the elderly. Singapore’s aging population with its complex health needs is likely to 
make up an increasing proportion of the workload of ED staff in the coming years.
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OBJECTIVES: To examine the incidence of Medicare Part D enrollees potentially 
affected by drug-drug interactions (DDI) and associated hospitalization, ER visits and 
death. METHODS: A retrospective cohort study of 2006 Medicare Part D enrollees 
from six states (Alabama, California, Florida, Mississippi, New York, and Ohio) was 
conducted. Enrollees with Part D claims for either the object or precipitant (precipitant 
alters the effects/pharmacokinetics of object) drug identiﬁ ed to result in a drug-drug 
interaction were included. Enrollees were identiﬁ ed as having a DDI if the object and 
precipitant drug were taken during overlapping dates, with the ﬁ rst day of overlap 
being the DDI event date. Medicare Part A records for 2006 were evaluated to examine 
hospitalizations and ER visits within 30 days of an object drug precipitation of the 
potential DDI. The Medicare beneﬁ ciary ﬁ le was used to examine death. RESULTS:
Data were available for 2,707,769 enrollees. Overall, 15.3% of enrollees were taking 
an object and precipitant drug, thus being at risk for a potential DDI. After controlling
for age, gender, ethnicity, and comorbidities, the odds ratio for hospitalization and for
ER visits when comparing enrollees with a DDI to enrollees taking an object drug 
without DDI potential were: 1.57 and 1.57 for warfarin DDI’s; 1.28 and 1.48 for
digoxin DDI’s; 1.37 and 1.04 for beta-blocker DDI’s; 1.27 and 1.09 for ACE/ARB 
inhibitor DDI’s; 2.20 and 1.90 for methotrexate DDI’s; 1.37 and 1.23 for clonidine
DDI’s. Signiﬁ cant outcomes were not found for pimozide, MAOI/SSRI, and thiopurine 
DDI’s. There was no increase in risk of mortality. CONCLUSIONS: Potential DDIs
are still a signiﬁ cant problem among the elderly. Intervention strategies to reduce 
the incidence of potential DDI’s should be a priority in CMS quality assurance 
activities.
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OBJECTIVES: The pharmacovigilance guidances have been implemented in many 
well developed countries, but in the developing countries it remains largely unclear. 
The purpose of this study was to review the current status of post-marketing drug 
safety surveillance in developing countries as deﬁ ned by low and lower-middle-income
economies and to compare it with some of the developed countries as deﬁ ned 
by high-income economies. METHODS: Using Pubmed, EMBASE, Cochrane, text-
books, and Internet search engines, an extensive literature review on post-marketing
drug safety surveillance systems were reviewed in terms of regulatory policy,
organizational structure, adverse drug reaction (ADR) reports, and safety monitoring 
system. The available data in the developing countries namely India, Zambia, 
Tanzania, China, Cuba, Ukraine, Malaysia, Chile and South Africa were then 
compared with that in the developed countries namely Netherlands, UK, and the
United States. RESULTS: Some developing countries like China and India are 
establishing pharmacovigilance centers and appear to be actively involved in post 
marketing surveillance. A handful of developing countries have a well planned strategy 
for pharmacovigilance. Many countries such as Kenya and Ethiopia do not have an 
ADR reporting system. Paucity of trained and experienced personnel, ﬁ nancial 
resources, and availability and irrational use of herbal medicines are some of the 
major obstacles in planning a well organized and structured ADR reporting system. 
The developing countries also lack well deﬁ ned guidelines on risk management. 
CONCLUSIONS: There is a deﬁ nite need for drug safety programs in the developing 
countries given the fact that these countries differ markedly in terms of type of disease 
prevalence, patient genotype and environment. A cooperative and exhaustive
effort by the regulatory authorities, physicians, as well as the pharmaceutical industry 
will be needed in order to create a functioning pharmacovigilance system in these 
countries.
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OBJECTIVES: We aimed to investigate associations between health-related quality of 
life (HRQoL) and health service utilization and to investigate whether HRQoL has
an independent inﬂ uence on health service utilization in addition to socio-demographic 
and morbidity variables. METHODS: A retrospective cross-sectional design was 
carried out among primary care patients in mainland China. Health services utilization 
was measured by the number of monthly outpatient consultation and the annual 
hospitalization rate. HRQoL was measured by the SF-36. The clustered regression 
model was adopted to calculate the independent inﬂ uence of HRQoL on health service 
utilization in addition to socio-demographic and morbidity variables. A total of 733
valid subjects were eventually recruited in this study. RESULTS: Three of the SF-36
subscales were reversely associated with the outpatient consultation, whereas two of 
the SF-36 subscales were reversely associated with inpatient consultation. In addition
to socio-demographic and morbidity variables, one subscale of the SF-36 (mental 
health) was reversely associated with the outpatient consultation with independent
inﬂ uence of 11.8 %; whereas one subscale of the SF-36 (general health) was reversely 
associated with the inpatient consultation with independent inﬂ uence of 26.0%.
CONCLUSIONS: HRQoL was reversely associated with health services utilization 
and the independent inﬂ uence of HRQoL on health services utilization was smaller 
than that of socio-demographic and morbidity variables among primary care patients
in mainland China.
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OBJECTIVES: To investigate the preliminary impact of hospital global budgeting 
on the quality of care in Taiwan. METHODS: The logistic regression analysis was
employed to explore, after adjusting for case-mix using Charlson Comorbidity Index 
score, SARS effect and time trend, the impact of global budgeting on the mortality 30
days after admission, readmission 30 days after discharge and infection. Hospital 
inpatient claims of National Health Insurance from 2000 to 2004 were used. Global 
budgeting implemented on July 1, 2002 was represented by a dummy variable in the
model. RESULTS: The mortality rates 30 days after admission were 3.81, 3.87, 3.8, 
4.11 and 3.91 respectively; while the readmission rates 30 days after discharge were
17.3, 18.1, 18.5, 18.8 and 19.5. The corresponding infection rates were 0.76, 0.78,
0.75, 0.83 and 0.79. After the implementation of hospital global budgeting, patients
in district hospitals had lower readmission possibilities and insigniﬁ cant difference in 
infection. However, patients in medical centers and regional hospitals had higher 
readmission but lower infection probabilities. Patients in all hospitals had lower prob-
ability of death. CONCLUSIONS: Since the sector global budgeting in the ﬁ rst two 
years incurred stronger competition among hospitals, larger hospitals such as medical
centers and regional hospitals generated higher readmission rates, resulting in lower 
readmission rates for district hospitals. Nevertheless the mortality rates as well as the
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infection possibilities were improved. The shrinkage of services of the district hospitals 
had attracted decision-makers’ attention, some measures were adopted. Future inpact 
is yet to be studied.
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OBJECTIVES: To determine the less costly alternative of parenteral nutrition in Public 
Health Care Institutions in Mexico. METHODS: A cost-minimization study was per-
formed comparing the use of RTU (considering four different formulations with 3.6 g, 
6.6 g, 11.2 g and 13.2 g of nitrogen) against equivalent CNF preparations made by a 
third-part company. This study compared all direct and indirect costs considering an 
institutional perspective based on data collected from the main Public Health Institu-
tion in Mexico. Costs associated with third-part services were estimated within a
Monte Carlo Simulation. Costs of the equivalent RTU TPN bags were obtained from 
a manufacturer. Results were evaluated with a Student t-test considering the mean use 
of 20 bags a day in order to evaluate if there is any signiﬁ cant differences between
the costs of in-hospital and third-part companies preparations for long-term use of 
TPN. RESULTS: Third-part services costs showed a triangular distribution according
to Monte Carlo results. RTU costs were 9.95%, 16.93%, 36.45% and 27.21% lower 
than CNF TPN for preparations with 3.6 g, 6.6 g, 11.2 g and 13.2 g of nitrogen 
respectively. T-test showed a signiﬁ cant difference in favor of RTU TPN for all evalu-
ated formulations (p  0.0001 for all). CONCLUSIONS: The use of RTU offers a 
signiﬁ cant less costly alternative for adult TPN when compared with equivalent third-
part CNF in Public Health Institutions in Mexico. The long-term adoption of the RTU 
TPN system can be associated with important cost-savings for public health institu-
tions in Mexico.
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OBJECTIVES: To identify and categorize publicly available cases of performance-
based health outcomes agreements. METHODS: We performed a systematic review 
of performance-based health outcomes agreements over the past 20 years (July 1998 
–October 2008) using publicly available databases and input from colleagues and
health care experts. We further developed a taxonomy of agreement types by induc-
tively organizing the cases identiﬁ ed according the timing, execution, and health out-
comes measured in the agreements. RESULTS: Our search yielded in excess of 60 
documents including peer reviewed articles, secondary publications, websites and in-
person communications. From this set, we identiﬁ ed 28 agreements categorized as 
coverage with evidence development, eight that were categorized as conditional treat-
ment continuation, and ten agreements categorized as performance-linked reimburse-
ment. Because of current national reimbursement policies, devices appear to be the 
best candidates in the US, whereas pharmaceuticals appear to the best candidates for 
EU and other non US payers. CONCLUSIONS: With a relatively small number of 
cases from which to draw conclusions, it is difﬁ cult to ascertain whether performance-
based health outcomes agreements signal a fundamental change in reimbursement
policies. Given the interest to date and the potential to meet the goals of interested 
stakeholders, these agreements have the potential to become more common in health
care. However, signiﬁ cant challenges including high transaction costs and insufﬁ cient 
information systems may limit the long-term impact and viability of health outcomes
based agreements. Future studies regarding the attitudes and perceptions of various 
stakeholders are needed, as well as evaluations of the results and experience with the
agreements implemented thus far.
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OBJECTIVES: The ISPOR Task Force for Good Research Practices for Measuring
Drug Costs in Cost-Effectiveness Analyses recently vetted a draft report suggesting 
that costs from a payer perspective be net all copayments. Our objective is to highlight 
the impact and challenges of including patient cost sharing in cost-effectiveness analy-
ses. METHODS: We used a 1-year decision model to calculate the incremental cost-
effectiveness ratio (ICER) of a biologic from the payer perspective. The biologic plus
usual care was compared to usual care. Effects and costs were taken from the litera-
ture. We assumed 50% of plans covered biologics as coinsurance and 50% as copay-
ments. The maximum coinsurance was assumed to be $2500. We assumed that 20% 
of the maximum coinsurance was attributable to the biologic. We assumed the average 
coinsurance for a biologic was 20% and the average copayment was $50. Sensitivity 
analyses were performed. RESULTS: The ICER was $114,813/QALY without 
accounting for patient cost sharing. With cost sharing the biologic drug cost was 4%
lower with an ICER of $98,144/QALY. Sensitivity analysis showed that a 5% increase 
in the rebate has a larger effect on the ICER than cost sharing. The amount of coinsur-
ance attributable to the treatment had the largest effect on cost sharing. CONCLU-
SIONS: Cost sharing does not affect the ICER when the copayment is ﬁ xed and
remains constant for all comparators. Data exists within plans to update inputs for 
many of our assumptions. Patient coinsurance levels should be assessed without the 
biologic in order to determine whether excess coinsurance could be attributed to the
biologic (drug of interest). Cost sharing should not be included if patients reach their 
maximum coinsurance without treatment. This analysis did not consider cost sharing 
associated with non-drug costs, which may increase the ICER due to more cost offsets 
for the biologic comparator.
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OBJECTIVES: We evaluated the ﬁ rst-year operation of Korean positive list system for 
pharmaceutical reimbursement through analyzing decisions accomplished by Drug 
Reimbursement Evaluation Committee (DREC) since we introduced this system in 
December 2006. METHODS: Ninety-four decisions made by DREC till October 2008 
were included in this analysis. Variables concerned in reimbursement decisions were
selected and regression analysis was carried out to explores which variables are likely 
to lead positive recommendations. RESULTS: DREC decided 54(57.4%) products to
be listed among total of 94 decisions. New molecular entity drugs and orphan drugs
account for 44.7% and 18.1% of all included drugs. Lack of evidence to prove cost-
effectiveness was the most common reason which lead negative recommendation (N 
 26, 65%) followed by lack of evidence for clinical effectiveness (N  5, 12.5%) and 
for both of them (N  4, 10%). In terms of clinical aspect, the number of RCT, Ana-
tomical Therapeutic Chemical (ATC) classiﬁ cation and orphan drugs did not have
signiﬁ cant inﬂ uence on the odds of positive decisions(p  0.05) except for improved 
extent of clinical beneﬁ t compared with comparators (p  0.001). In other aspects,
less medical cost was a positive factor and additional budget impact was a negative 
factor in relation to recommendation (p  0.001). CONCLUSIONS: Lack of evidence 
for cost-effectiveness was the most common reason to lead negative recommendation. 
Many clinical factors which we considered seemed not to be signiﬁ cantly associated 
with recommendations in Korea. DREC recently decided reference range of cost-
effectiveness threshold reﬂ ecting disease severity, social burden, quality of life and 
aspect of renovation after in-depth discussions. According to newly established crite-
ria, evaluation would be conducted comprehensively in decision making for pharma-
ceutical reimbursement.
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OBJECTIVES: To examine associations between health status and attitude about
health insurance in Medical Expenditure Panel Survey population (MEPS). Studies
have shown that lack of health insurance is associated with important clinical
characteristics, including use of fewer health care services, delaying-seeking medical 
care and forgoing necessary care for potentially serious symptoms. METHODS:
The Household Component (HC) public use ﬁ le from the 2005 MEPS data, a nation-
ally representative survey of the noninstitutionalized population was used in the
United States. Health status and attitudes towards health insurance were measured 
using the Self-Administered Questionnaire (SAQ) data collected within MEPS.
Data were analyzed using SAS 9.1.3. Descriptive statistics were obtained using 
PROC UNIVARIATE. PROC CANCORR was used to measure canonical correlation
between set of attitude about health insurance variables and set of health status 
variables. RESULTS: The mean age of sample was 46.33 years (Standard deviation:
17.69). the majority were female 60.6% and white 77.2%. The ﬁ rst canonical cor-
relation was 0.32 (11% overlapping variance); the second was 0.08 (0.6% overlapp-
ing variance). All four pairs of canonical variates accounted for the signiﬁ cant
relationships between the two sets of variables. Canonical Redundancy Analysis 
obtained using PROC CANCORR found ﬁ rst health status variate accounting 4% 
of variance in attitude about health insurance variable set. CONCLUSIONS: A per-
son’s health status and their attitude about health insurance are moderately related. 
Further studies need to be conducted with more measures of attitude about health 
insurance to determine exact relationship between health status and attitude about 
health insurance.
